A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Public ClinicalTrials.gov record NCT06157892. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Study identification
- NCT ID
- NCT06157892
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2024 (Actual)
- Primary completion
- Jul 28, 2029 (Estimated)
- Completion
- Jul 28, 2029 (Estimated)
- Last update posted
- Jul 22, 2026
2024 – 2029
United States locations
- U.S. sites
- 77
- U.S. states
- 18
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner-University Medical Center Tucson Campus | Tucson | Arizona | 85704 | — |
| Banner-University Medical Center Tucson Campus | Tucson | Arizona | 85719 | — |
| The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal | Tucson | Arizona | 85719 | — |
| University of Arizona Cancer Center - North Campus | Tucson | Arizona | 85719 | — |
| The University of Arizona Cancer Center-Main | Tucson | Arizona | 85724 | — |
| UC Irvine Health - Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| UC Irvine Medical Center | Orange | California | 92868 | — |
| University of California, San Francisco | HDFCCC - Hematopoietic Malignancies | San Francisco | California | 94158 | — |
| UCLA Department of Medicine - Hematology & Oncology | Santa Monica | California | 90404 | — |
| UCLA Hematology/Oncology - Parkside | Santa Monica | California | 90404 | — |
| Colorado West Healthcare System, dba Community Hospital | Grand Junction | Colorado | 81505 | — |
| Colorado West Healthcare, dba Grand Valley Oncology | Grand Junction | Colorado | 81505 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center - International Plaza | Tampa | Florida | 33607 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Moffitt Cancer Center - McKinley Campus | Tampa | Florida | 33612 | — |
| Moffitt McKinley Hospital | Tampa | Florida | 33612 | — |
| Moffitt Cancer Center at Wesley Chapel | Wesley Chapel | Florida | 33544 | — |
| Georgia Cancer Specialists - Athens | Athens | Georgia | 30606 | — |
| Georgia Cancer Specialists - Annex | Atlanta | Georgia | 30341 | — |
| Atlanta Cancer Care - Atlanta | Atlanta | Georgia | 30342 | — |
| Georgia Cancer Specialists-Northside | Atlanta | Georgia | 30342 | — |
| Northside Hospital, Inc.- Central Research Department | Atlanta | Georgia | 30342 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Georgia Cancer Specialists - Blairsville | Blairsville | Georgia | 30512 | — |
| Georgia Cancer Specialists - Canton | Canton | Georgia | 30115 | — |
| Atlanta Cancer Care - Cumming | Cumming | Georgia | 30041 | — |
| Georgia Cancer Specialists - Cumming | Cumming | Georgia | 30041 | — |
| Georgia Cancer Specialists - Decatur | Decatur | Georgia | 30033 | — |
| Suburban Hematology-Oncology Associates - Duluth | Duluth | Georgia | 30096 | — |
| Suburban Hematology-Oncology Associates- Lawrenceville | Lawrenceville | Georgia | 30046 | — |
| Georgia Cancer Specialists - Macon | Macon | Georgia | 31217 | — |
| Georgia Cancer Specialists - Marietta | Marietta | Georgia | 30060 | — |
| Memorial Hospital | Shiloh | Illinois | 62269 | — |
| Siteman Cancer Center - Shiloh | Shiloh | Illinois | 62269 | — |
| Massachusetts General Hospital. | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute- Chestnut Hill | Newton | Massachusetts | 02459 | — |
| Siteman Cancer Center - St Peters | City of Saint Peters | Missouri | 63376 | — |
| Siteman Cancer Center - West County | Creve Coeur | Missouri | 63141 | — |
| Siteman Cancer Center - North County | Florissant | Missouri | 63031 | — |
| Saint Luke's Cancer Institute LLC | Kansas City | Missouri | 64111 | — |
| Saint Luke's Hospital Investigational Pharmacy | Kansas City | Missouri | 64111 | — |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine - Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Siteman Cancer Center - South County | St Louis | Missouri | 63129 | — |
| Renown Regional Medical Center | Reno | Nevada | 89502 | — |
| Memorial Sloan Kettering Cancer Center - Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| MSK Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| Memorial Sloan Kettering - Monmouth | Middletown | New Jersey | 07748 | — |
| MSK Monmouth. | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering - Bergen | Montvale | New Jersey | 07645 | — |
| MSK Bergen. | Montvale | New Jersey | 07645 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Memorial Sloan Kettering Cancer Center - Commack | Commack | New York | 11725 | — |
| MSK Commack. | Commack | New York | 11725 | — |
| Memorial Sloan Kettering - Westchester | Harrison | New York | 10604 | — |
| MSK Westchester. | Harrison | New York | 10604 | — |
| Investigational Drug Service | Long Island City | New York | 11101 | — |
| Memorial Sloan Kettering Cancer Center - Main Hospital | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Memorial Sloan Kettering- Nassau | Uniondale | New York | 11553 | — |
| MSK Nassau. | Uniondale | New York | 11553 | — |
| Zangmeister Cancer Center | Columbus | Ohio | 43219 | — |
| Saint Francis Hospital / Bon Secours - South Carolina | Greenville | South Carolina | 29607 | — |
| Sarah Cannon Research Institute - Pharmacy | Nashville | Tennessee | 37203 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology-Nashville/Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Providence Health and Services Washington and Montana | Renton | Washington | 98057 | — |
| Harborview Medical Center | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington | Seattle | Washington | 98109 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
| University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison | Wisconsin | 53718 | — |
| Carbone Cancer Center / University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06157892, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06157892 live on ClinicalTrials.gov.